Literature DB >> 21123522

Molecular targets in meningococci: efficient routine characterization and optimal outbreak investigation in conjunction with routine surveillance of the meningococcal group B vaccine candidate, fHBP.

Jay Lucidarme1, Lynne S Newbold, Jamie Findlow, Stefanie Gilchrist, Stephen J Gray, Anthony D Carr, James Hewitt, Edward B Kaczmarski, Ray Borrow.   

Abstract

In 2007, recommendations were proposed for the molecular typing of meningococci. Multilocus sequence typing (MLST) was recommended to guide national and international disease management and facilitate studies of population biology and evolution. Sequencing of porA variable regions (VRs) 1 and 2 and the fetA VR was recommended for monitoring antigenic distribution and investigating potential outbreaks. porB characterization was recommended if further resolution was required. Several investigational "group B" meningococcal vaccines, including two in the advanced stages of development, incorporate factor H-binding protein (fHBP). The requirement for routine surveillance of fhbp places additional pressure on reference laboratories, both financially and in terms of labor. This study investigated the optimal and most efficient molecular typing schemes for (i) routine meningococcal characterization and (ii) the investigation of potential outbreaks, in conjunction with routine surveillance of fhbp. All invasive disease isolates received by the Health Protection Agency Meningococcal Reference Unit between July 2007 and June 2008 (n = 613) were characterized in terms of capsular group, porA, fetA VR, fhbp, and sequence type (ST). Following capsular grouping and porA genosubtyping, several predominant capsular group-porA combinations were identified. The levels of additional resolution afforded by fetA and fhbp were comparable and partially complementary. fhbp constitutes an effective substitute for fetA as a routine marker of antigenic distribution, thereby reducing costs in conjunction with fhbp surveillance. MLST afforded markedly superior resolution overall and is the optimal scheme for investigating outbreaks in which (i) typing data are unavailable for the index case or (ii) the index case possesses a known, predominant capsular group-porA repertoire.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21123522      PMCID: PMC3067353          DOI: 10.1128/CVI.00401-10

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  31 in total

1.  Functional significance of factor H binding to Neisseria meningitidis.

Authors:  Muriel C Schneider; Rachel M Exley; Hannah Chan; Ian Feavers; Yu-Hoi Kang; Robert B Sim; Christoph M Tang
Journal:  J Immunol       Date:  2006-06-15       Impact factor: 5.422

2.  Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B.

Authors:  Subramonia Pillai; Alan Howell; Kristin Alexander; B Erin Bentley; Han-Qian Jiang; Karita Ambrose; Duzhang Zhu; Gary Zlotnick
Journal:  Vaccine       Date:  2005-03-18       Impact factor: 3.641

3.  A universal vaccine for serogroup B meningococcus.

Authors:  Marzia M Giuliani; Jeannette Adu-Bobie; Maurizio Comanducci; Beatrice Aricò; Silvana Savino; Laura Santini; Brunella Brunelli; Stefania Bambini; Alessia Biolchi; Barbara Capecchi; Elena Cartocci; Laura Ciucchi; Federica Di Marcello; Francesca Ferlicca; Barbara Galli; Enrico Luzzi; Vega Masignani; Davide Serruto; Daniele Veggi; Mario Contorni; Maurizio Morandi; Alessandro Bartalesi; Vanda Cinotti; Donatella Mannucci; Francesca Titta; Elisa Ovidi; Jo Anne Welsch; Dan Granoff; Rino Rappuoli; Mariagrazia Pizza
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-06       Impact factor: 11.205

4.  The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance.

Authors:  Guillermo Madico; Jo Anne Welsch; Lisa A Lewis; Anne McNaughton; David H Perlman; Catherine E Costello; Jutamas Ngampasutadol; Ulrich Vogel; Dan M Granoff; Sanjay Ram
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

5.  Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms.

Authors:  M C Maiden; J A Bygraves; E Feil; G Morelli; J E Russell; R Urwin; Q Zhang; J Zhou; K Zurth; D A Caugant; I M Feavers; M Achtman; B G Spratt
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

6.  Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit.

Authors:  Stephen J Gray; Caroline L Trotter; Mary E Ramsay; Malcolm Guiver; Andrew J Fox; Raymond Borrow; Richard H Mallard; Edward B Kaczmarski
Journal:  J Med Microbiol       Date:  2006-07       Impact factor: 2.472

Review 7.  Standardized nonculture techniques recommended for European reference laboratories.

Authors:  Andrew J Fox; Muhamed-Kheir Taha; Ulrich Vogel
Journal:  FEMS Microbiol Rev       Date:  2006-11-01       Impact factor: 16.408

8.  Multilocus sequence typing of Neisseria meningitidis directly from clinical samples and application of the method to the investigation of meningococcal disease case clusters.

Authors:  Andrew Birtles; Katie Hardy; Stephen J Gray; Suzanne Handford; Edward B Kaczmarski; Valerie Edwards-Jones; Andrew J Fox
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

9.  Identification of variable region differences in Neisseria meningitidis class 3 protein sequences among five group B serotypes.

Authors:  G A Zapata; W F Vann; Y Rubinstein; C E Frasch
Journal:  Mol Microbiol       Date:  1992-12       Impact factor: 3.501

10.  Early treatment with parenteral penicillin in meningococcal disease.

Authors:  K Cartwright; S Reilly; D White; J Stuart
Journal:  BMJ       Date:  1992-07-18
View more
  6 in total

1.  Neisseria meningitidis disease-associated clones in Amazonas State, Brazil.

Authors:  Luciete A Silva; Beatriz Coronato; Jessica Schlackman; Jane W Marsh; Chinelo Ezeonwuka; Andréia C L Fernandes; Victor C Souza; Lirna S da Silva; Elaine F Q de Amorim; Felipe G Naveca; Bernardino C de Albuquerque; Alcirene Amaral; Ana L S Souza; Filipe A Carvalho-Costa; Mustapha M Mustapha; Lee H Harrison; David E Barroso
Journal:  Infect Dis (Lond)       Date:  2018-04-06

2.  Molecular and serological diversity of Neisseria meningitidis carrier strains isolated from Italian students aged 14 to 22 years.

Authors:  Roberto Gasparini; Maurizio Comanducci; Daniela Amicizia; Filippo Ansaldi; Paola Canepa; Andrea Orsi; Giancarlo Icardi; Emanuela Rizzitelli; Gabriella De Angelis; Stefania Bambini; Monica Moschioni; Sara Comandi; Isabella Simmini; Giueseppe Boccadifuoco; Brunella Brunelli; Marzia Monica Giuliani; Mariagrazia Pizza; Donatella Panatto
Journal:  J Clin Microbiol       Date:  2014-03-19       Impact factor: 5.948

3.  A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II).

Authors:  Susanna Esposito; Roman Prymula; Gian Vincenzo Zuccotti; Fang Xie; Michelangelo Barone; Peter M Dull; Daniela Toneatto
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 4.  Interplay Between Virulence and Variability Factors as a Potential Driver of Invasive Meningococcal Disease.

Authors:  Emilio Siena; Margherita Bodini; Duccio Medini
Journal:  Comput Struct Biotechnol J       Date:  2018-02-15       Impact factor: 7.271

5.  Molecular characterization of invasive Neisseria meningitidis strains isolated in Chile during 2010-2011.

Authors:  Gisselle N Barra; Pamela A Araya; Jorge O Fernandez; Jean-Marc Gabastou; Juan Carlos Hormazábal; Mabel Seoane; Paola C Pidal; Maria T Valenzuela; Ana Belén Ibarz-Pavón
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

6.  4CMenB vaccine induces elite cross-protective human antibodies that compete with human factor H for binding to meningococcal fHbp.

Authors:  Daniele Veggi; Federica Bianchi; Laura Santini; Paola Lo Surdo; Chelsy C Chesterman; Werner Pansegrau; Nicoletta Bechi; Ying Huang; Vega Masignani; Mariagrazia Pizza; Rino Rappuoli; Matthew J Bottomley; Roberta Cozzi; Domenico Maione
Journal:  PLoS Pathog       Date:  2020-10-02       Impact factor: 6.823

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.